Yuhan Corporation
Clinical trials sponsored by Yuhan Corporation, explained in plain language.
A South Korean pharmaceutical company developing drugs and vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New generic combo pill for high blood pressure put to the test Results expected Sep 2026 (estimated)
- Healthy men needed to test experimental Drug's safety Results expected Mar 2027 (estimated)
- New drug YH32364 targets Hard-to-Treat cancers in first human trial Results expected Jun 2027 (estimated)
- New hope for chronic hives? experimental drug lesigercept enters Mid-Stage trial Results expected Jun 2027 (estimated)
-
New lung cancer pill shows promise in Head-to-Head trial
Disease control CompletedThis Phase 3 trial tested a new targeted therapy, lazertinib, against the standard drug gefitinib in 393 people with advanced EGFR-mutated non-small cell lung cancer. The goal was to see if lazertinib could keep cancer from growing longer. Participants took either lazertinib or g…
Phase 3 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New bronchitis drug shows promise in large trial
Symptom relief CompletedThis Phase 3 trial tested a new drug called YHP2401 against two other drugs for acute bronchitis. 286 adults with cough and phlegm took one of the treatments for 7 days. The goal was to see if YHP2401 works better at reducing symptoms.
Phase 3 • Sponsor: Yuhan Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
Healthy volunteers needed to compare two forms of a cholesterol drug
Knowledge-focused CompletedThis study checks if a new version of a drug (YHP2511) is absorbed into the body the same way as the original (YHP2511A). About 60 healthy adults aged 19 to 55 will take a single dose of each version on separate days. The goal is to see if the two versions are bioequivalent, mean…
Phase 1 • Sponsor: Yuhan Corporation • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Healthy volunteers test two antibiotic versions for equivalence
Knowledge-focused CompletedThis study checked if two different versions of an antibiotic (amoxicillin/clavulanic acid) work the same in the body. 63 healthy adults took a single dose of each drug in a random order. The goal was to see if the levels of drug in the blood were similar enough to consider the d…
Phase 1 • Sponsor: Yuhan Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC